These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 1671782)

  • 21. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.
    Leslie WD; Abrams DN; Greenberg CR; Hobson D
    J Nucl Med; 1996 Oct; 37(10):1589-91. PubMed ID: 8862288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
    Hierholzer J; Cordes M; Schelosky L; Barzen G; Poewe W; Henkes H; Keske U; Horowski R; Felix R
    Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial experience with SPECT examinations using [123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease.
    Cordes M; Henkes H; Laudahn D; Bräu H; Kramp W; Girke W; Hierholzer J; Eichstädt H; Felix R
    Eur J Radiol; 1991; 12(3):182-6. PubMed ID: 1830273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine D2 receptor imaging with iodine-123-iodobenzamide SPECT in idiopathic rotational torticollis.
    Hierholzer J; Cordes M; Schelosky L; Richter W; Keske U; Venz S; Semmler W; Poewe W; Felix R
    J Nucl Med; 1994 Dec; 35(12):1921-7. PubMed ID: 7989970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism.
    Schwarz J; Tatsch K; Arnold G; Gasser T; Trenkwalder C; Kirsch CM; Oertel WH
    Neurology; 1992 Mar; 42(3 Pt 1):556-61. PubMed ID: 1549216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.
    Jauss M; Krack P; Franz M; Klett R; Bauer R; Gallhofer B; Dorndorf W
    Mov Disord; 1996 Nov; 11(6):726-8. PubMed ID: 8914102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates.
    Innis RB; Malison RT; al-Tikriti M; Hoffer PB; Sybirska EH; Seibyl JP; Zoghbi SS; Baldwin RM; Laruelle M; Smith EO
    Synapse; 1992 Mar; 10(3):177-84. PubMed ID: 1532675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability.
    Verhoeff NP; Kapucu O; Sokole-Busemann E; van Royen EA; Janssen AG
    J Nucl Med; 1993 Dec; 34(12):2076-84. PubMed ID: 8254390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine D2 receptor binding is reduced in Wilson's disease: correlation of neurological deficits with striatal 123I-iodobenzamide binding.
    Oder W; Brücke T; Kollegger H; Spatt J; Asenbaum S; Deecke L
    J Neural Transm (Vienna); 1996; 103(8-9):1093-103. PubMed ID: 9013397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SPECT study of the nigrostriatal dopaminergic system in Huntington's disease.
    Hwang WJ; Yao WJ
    J Neuroimaging; 2013 Apr; 23(2):192-6. PubMed ID: 22211920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease.
    Tatsch K; Schwarz J; Oertel WH; Kirsch CM
    Nucl Med Commun; 1991 Aug; 12(8):699-707. PubMed ID: 1838142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.
    Tibbo P; Silverstone PH; McEwan AJ; Scott J; Joshua A; Golberg K
    J Psychiatry Neurosci; 1997 Jan; 22(1):39-45. PubMed ID: 9002391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Striatal uptake of I-123-beta-CIT and I-123-IBZM in patients with extrapyramidal symptoms].
    Bettin S; Kämpfer I; Seese A; Schäfer A; Reuter M; Lössner J; Dietrich J; Wagner A; Knapp WH
    Nuklearmedizin; 1997 Aug; 36(5):167-72. PubMed ID: 9380528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humans.
    Toyama H; Ichise M; Ballinger JR; Fornazzari L; Kirsh JC
    Ann Nucl Med; 1993 Feb; 7(1):29-38. PubMed ID: 8461237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
    Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM
    J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
    Dresel S; Mager T; Rossmüller B; Meisenzahl E; Hahn K; Möller HJ; Tatsch K
    Eur J Nucl Med; 1999 Aug; 26(8):862-8. PubMed ID: 10436199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Brain SPECT with 123I-labelled iodobenzamide (IBZM): aspects of semiquantitative evaluation].
    Menzel C; Grünwald F; Klemm E; Broich K; Kasper S; Reichmann K; Hotze AL; Biersack HJ
    Nuklearmedizin; 1993 Oct; 32(5):227-30. PubMed ID: 8233842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia.
    Schwarz J; Tatsch K; Vogl T; Kirsch CM; Trenkwalder C; Arnold G; Gasser T; Oertel WH
    Mov Disord; 1992; 7(1):58-61. PubMed ID: 1532631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical impact of cerebral dopamine-D2 receptor scintigraphy].
    Larisch R; Klimke A
    Nuklearmedizin; 1998; 37(7):245-50. PubMed ID: 9830615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography.
    van Royen E; Verhoeff NF; Speelman JD; Wolters EC; Kuiper MA; Janssen AG
    Arch Neurol; 1993 May; 50(5):513-6. PubMed ID: 8489409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.